PLAQUE AND BRAIN INFLAMMATION IN SYMPTOMATIC CAROTID STENOSIS: ROLE OF THE FICOLIN-2 STATEMENT

Lab values

• Patients with inflammatory or autoimmune disease, hepatocellular insufficiency, acute or chronic infection, active malignancy, myocardial infarction or major surgery within the previous 30 days of index hospitalization according to the investigator, - Patients with severe renal insufficiency (estimated GFR < 30 ml/min at inclusion or known dialysis), - Patients with contraindication to MRI (agitation, claustrophobia, pacemaker, metallic (ferromagnetic) body, a known allergy to gadolinium) according to the investigator’s judgment, - Patients currently enrolled in another clinical trial including investigational medicinal products, - Female patient who is pregnant or lactating, or is of child-bearing and who did not agree to use highly effective methods of birth control throughout the study, - Patient without health coverage, - Patient under legal protection.

• -Patients 18 years or over, -Signed written informed consent before any study specific intervention, -Probable ipsilateral transient ischemic attack (TIA – which involve a focal speech/language, motor or visual deficit referable to the distribution of a carotid artery and lasting less than 48 hours from the onset) OR retinal artery occlusion ≤ 48h OR ischemic stroke ≤ 48h from the onset,- Atherosclerotic carotid stenosis between 50% and 99% (NASCET method), as confirmed by one of the imaging examinations (among: Doppler ultrasound, MR angiography, CT angiography, catheter angiography) performed after index TIA or ischemic stroke- - No other identified cause of TIA, ischemic stroke or retinal artery occlusion,